Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

Some of the best links we picked up around the internet

This week’s update looks at a Phase 1 clinical trial for a new meganuclease-edited CAR T-cell therapy for Non-Hodgkin lymphoma (NHL).

Researchers can manipulate genomes at the single-base level, but they still struggle to predict and detect the editing outcomes precisely. Eric Paul...